ACU193 for Early Alzheimer's Disease
(ALTITUDE-AD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are using cholinesterase inhibitors or memantine for Alzheimer's symptoms, you must keep the doses stable for at least three months before starting the trial and try to maintain them throughout the study.
Is ACU193 safe for humans?
ACU193 is a new treatment being tested for Alzheimer's disease, and while specific safety data for ACU193 isn't available, similar treatments like aducanumab have shown some safety concerns, such as amyloid-related imaging abnormalities (changes seen in brain scans). It's important to discuss potential risks with the trial team.12345
How is the drug ACU193 different from other Alzheimer's treatments?
ACU193 is unique because it is a monoclonal antibody that specifically targets soluble amyloid β oligomers, which are believed to be the most toxic form of amyloid β contributing to Alzheimer's disease. Unlike other treatments that target amyloid plaques or monomers, ACU193 is the first to focus on these oligomers, aiming to stop or reverse cognitive decline associated with Alzheimer's.34567
What data supports the effectiveness of the drug ACU193 for early Alzheimer's disease?
ACU193 is the first treatment designed to specifically target amyloid β oligomers, which are believed to be directly responsible for memory and cognitive decline in Alzheimer's disease. This approach is based on the hypothesis that blocking these oligomers could stop or reverse cognitive decline, a strategy not yet tested in previous trials.3891011
Who Is on the Research Team?
Eric Siemers, MD
Principal Investigator
Acumen Pharmaceuticals
Eric Siemers, MD
Principal Investigator
Acumen Pharmaceuticals
Are You a Good Fit for This Trial?
This trial is for individuals with early Alzheimer's Disease who can attend regular infusions every four weeks. Specific eligibility details are not provided, but typically participants must meet certain health criteria and agree to follow the study procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Double-blind Treatment (DBT) Period
Participants receive either sabirnetug or placebo as an intravenous infusion every four weeks
Open-Label Extension (OLE) Period
Participants receive sabirnetug as an intravenous infusion every four weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ACU193
Find a Clinic Near You
Who Is Running the Clinical Trial?
Acumen Pharmaceuticals
Lead Sponsor